Glofitamab alone or with chemo for relapsed aggressive b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of aggressive B-cell lymphoma that has come back or not responded to at least one previous treatment.
- You are expected to live at least 12 weeks, and your overall health is reasonably good (ECOG score 0-2).
- You have at least one measurable tumor that is at least 1.5 cm in the lymph nodes or 1 cm outside the lymph nodes, seen on a CT scan.
- You cannot have had certain previous treatments, including glofitamab or other similar bispecific antibodies.
- You cannot have significant heart, lung, or other major medical conditions, or active infections.
- You must not be pregnant or planning to become pregnant during the study or for 18 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
This study tests a new combination of drugs for people with aggressive B-cell lymphoma that has not gotten better or has come back. The goal is to see if the combination helps control the cancer.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
Hear when a new Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.